Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of September 21, 2026, AUPH trades at $17.00 with a market cap of $2.25B and a P/E ratio of 7.06. AUPH moved +0.56% today. Year to date, AUPH is +5.96%; over the trailing twelve months it is +31.11%. Its 52-week range spans $6.55 to $19.25. Analyst consensus is buy with an average price target of $18.00. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for AUPH combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $17.00 |
| Market Cap | $2.25B |
| P/E Ratio | 7.06 |
| EPS | $2.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.25 |
| 52-Week Low | $6.55 |
| Volume | 1.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $311.51M |
| Net Income | $314.11M |
| Gross Margin | 90.36% |
3 analysts cover AUPH: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.00.